NFAT5 and ischemia: Treatment with the proteasome inhibitor MG-132 (5 μM) significantly prevented the downregulation of TonEBP (Figure 1e), suggesting the involvement of proteasome activation in the enhanced degradation of TonEBP under ischemia.